Komzifti is an advanced anticancer therapy developed for the treatment of adults with relapsed or refractory Acute Myeloid Leukemia (AML) harboring a susceptible Nucleophosmin 1 (NPM1) mutation. It is specifically indicated for patients who have no satisfactory alternative treatment options, addressing a critical unmet medical need in high-risk AML management.

Designed to target the molecular pathways driven by NPM1 mutations, Komzifti provides a focused therapeutic approach aimed at improving disease control in a population with limited clinical responses to conventional regimens. Its formulation and mechanism are optimized to support enhanced antileukemic activity while maintaining rigorously monitored safety and quality standards.

Komzifti serves as a promising option for clinicians seeking mutation-specific therapy in relapsed or refractory AML, offering renewed possibility in cases where traditional treatments have proven insufficient.